Middle East & Africa Biologics Market Size & Outlook
Related Markets
MEA biologics market highlights
- The MEA biologics market generated a revenue of USD 7,153.2 million in 2024.
- The market is expected to grow at a CAGR of 7.4% from 2025 to 2030.
- In terms of segment, monoclonal antibodies (mabs) was the largest revenue generating product in 2024.
- Antisense & RNAi Therapeutics is the most lucrative product segment registering the fastest growth during the forecast period.
MEA data book summary
| Market revenue in 2024 | USD 7,153.2 million |
| Market revenue in 2030 | USD 10,976.2 million |
| Growth rate | 7.4% (CAGR from 2025 to 2030) |
| Largest segment | Monoclonal antibodies (mabs) |
| Fastest growing segment | Antisense & RNAi Therapeutics |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal antibodies (MABs), Vaccines, Recombinant Proteins, Antisense & RNAi Therapeutics |
| Key market players worldwide | Samsung BioLogics, Amgen Inc, Novo Nordisk A/S ADR, AbbVie Inc, Sanofi SA, Johnson & Johnson, Celltrion Healthcare, Bristol-Myers Squibb Co, Eli Lilly and Co, Roche Holding AG ADR |
Other key industry trends
- In terms of revenue, MEA region accounted for 1.8% of the global biologics market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 110,546.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biologics Market Scope
Biologics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Celltrion Healthcare | View profile | 51-100 | Incheon, Inch'on-jikhalsi, South Korea, Asia | http://www.celltrionhealthcare.com/ |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | https://www.samsungbiologics.com/ |
| Novo Nordisk A/S ADR | View profile | 66015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | https://www.novonordisk.com |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Roche Holding AG ADR | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Amgen Inc | View profile | 26700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | https://www.amgen.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Middle East & Africa biologics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics market will help companies and investors design strategic landscapes.
Monoclonal antibodies (mabs) was the largest segment with a revenue share of 69.01% in 2024. Horizon Databook has segmented the Middle East & Africa biologics market based on monoclonal antibodies (mabs), vaccines, recombinant proteins, antisense & rnai therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
MEA market of biologics is estimated to have the lowest market penetration as this industry is at a nascent stage in the region in the current scenario. However, with growing awareness as well as demand for biologics amongst the population in the region, is expected to have a positive impact on the growth of the market in this region in the coming years.
Reasons to subscribe to Middle East & Africa biologics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa biologics market databook
-
Our clientele includes a mix of biologics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa biologics market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa biologics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Middle East & Africa Biologics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
